What is Sparsentan Filspari?

Sparsentan, sold under the brand nameFilspari, is a drug used to treatprimary immunoglobulin A nephropathy. Sparsentane is an endothelin and angiotensin II receptor antagonist.

The primary indication for sparsentan is the treatment of adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for rapid disease progression, particularly those with a urine protein to creatinine ratio (UPCR) ≥1.5g/g. This type of kidney disease is particularly common in my country and has a serious impact on patients' kidney function, and may even lead to end-stage renal disease, that is, uremia. The emergence of sparsentan provides new treatment options for these patients.

In clinical trials, sparsentane has demonstrated significant efficacy. Compared with irbesartan, after 36 weeks of treatment, sparsentan was able to reduce patients' proteinuria levels to a greater extent, which is an important sign of improvement in renal function. In addition, from the perspective of long-term renal function results, sparsentane can also effectively slow down the decline of renal function and protect patients' kidneys from further damage.

However, the use of Sparsentine comes with certain caveats. Due to its potential risk of hepatotoxicity, patients require close monitoring of liver function during use, especially during the first year of treatment, with monthly liver function tests required. At the same time, sparsentan should not be combined with certain drugs such as ARB, ERA or aliskiren to avoid possible drug interactions.

Although sparsentane is not currently on the market in China, its excellent performance in clinical trials has attracted widespread attention from the domestic medical community and patients. With further research and approval procedures progressing, we look forward to this innovative drug entering the domestic market as soon as possible, bringing hope to more IgAN patients.

xa0

Reference link:https://en.wikipedia.org/wiki/Sparsentan